drugset / Trial / NCT04359329

Estrogen Patch for COVID-19 Symptoms

NCT04359329

Phase 2 Terminated 2 enrolled Sharon Nachman
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if estrogen, a female sex hormone, given as a patch placed on skin of COVID19 positive or presumptive positive patients for 7 days can reduce the severity of COVID19 symptoms compared to regular care. This study has two study groups. One group will receive the study drug, a single-use Climara 25cm2 estrogen patch. The other group will receive standard of care. Participants will be asked questions about their symptoms for up 6 times in up to 45 days.

Timeline

Start
2020-04-20
Primary completion
2020-07-30
Completion
2020-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 100 ug Other

Indications